Life Sciences Tools and Services

Lifecore Biomedical

Lifecore Biomedical released FY2026 Q1 earnings on May 6 Pre-Market (EST), actual revenue USD 23.19 M (forecast USD 26.14 M), actual EPS USD -0.4251 (forecast USD -0.2966)

Lifecore Biomedical to Release FY2026 Q1 Earnings on May 6 Pre-Market EST, Forecast Revenue USD 25.96 M, EPS USD -0.29

Lifecore Biomedical signs CDMO Manufacturing Services Agreement

Lifecore Biomedical Inc. to Attend the 44th Annual J.P. Morgan Healthcare Conference

Hewitt Recommends Healthcare Stocks

Lifecore Biomedical released FY2025 earnings on August 7 Pre-Market EST, actual revenue USD 128.87 M (forecast USD 75.12 M), actual EPS USD -1.2739 (forecast USD -0.47)

Lifecore Biomedical released FY2025 Q4 earnings on August 7, Pre-Market EST, with actual revenue of USD 35.75 M (forecast USD 35.15 M) and actual EPS of USD -0.1613 (forecast USD -0.16)

Lifecore Biomedical to Release FY2025 Q4 Earnings on August 7 After-Market (EST), Forecast Revenue USD 35.36 M, EPS USD -0.095

Lifecore's Compensation Committee Approves Stock Option Grants

Institutional Investors Adjust Lifecore Biomedical's Shareholding Proportion

Law Firm Investigating Potential Improper Conduct at Lifecore Biomedical

Aron R. English Disposes of Lifecore Biomedical Common Stock

Aron R. English Reports Disposition of Lifecore Biomedical Common Stock

Aron English reports disposal of Lifecore Biomedical Inc. common stock

Lifecore Grants Equity Incentives to New Executive

Lifecore Biomedical released FY2025 Q3 earnings on April 3 After-Market EST, actual revenue USD 31.11 M (forecast USD 33.23 M), actual EPS USD -0.2917 (forecast USD -0.15)

Lifecore Biomedical released FY2025 9 Months Earnings on April 3 After-Market (EST), actual revenue 92.42 M USD, actual EPS -1.2532 USD

Lifecore Biomedical Inc Reports Quarterly Financial Results with Adjusted Loss of $0.47 per Share

Lifecore Biomedical to release FY2025 Q3 earnings on April 3 After-Market EST, forecast revenue 33.23 M USD, EPS -0.15 USD

Lifecore Biomedical, Inc. Expects Mid-Term and Long-Term Growth with Annual Revenue Potential of $300 Million

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Lifecore Biomedical(LFCR.US) 2025 年第二季度业绩电话会

LFCR

William Blair analyst Max Smock has maintained a Buy rating on Lifecore (LFCR) despite weak Q1 results, citing confidence in the company's 2026 targets and an attractive risk-reward profile. Although Q1 revenue and adjusted EBITDA fell short of expectations, management's reaffirmation of 2026 goals indicates a positive medium-term outlook. Smock highlights the upcoming earnings call as crucial for clarifying the quarterly shortfall and strategies for achieving future guidance. He acknowledges risks but believes the stock remains a strong buy. Craig-Hallum also reiterated a Buy rating on Lifecore.

Tip Ranks

ICON

Simulations Plus

Analyst Reiterates Buy on Lifecore Despite Weak Q1, Citing Confidence in 2026 Targets and Attractive Risk-Reward

Earnings Watch

Lifecore Biomedical | 10-Q: FY2026 Q4 Revenue: USD 23.19 M

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update | LFCR Stock News

StockTitan

Lifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update | LFCR Stock News

ATNF

SBIO

LABU

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc. | BBCMF Stock News

180 Life Sciences

iShares Biotechnology ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc. | BBCMF Stock News

Lifecore Biomedical Earnings Call Signals Profitable Shift

Lifecore Biomedical Earnings Call Signals Profitable Shift

Lifecore Biomedical (NASDAQ:LFCR) is set to release its earnings on Thursday, April 2, after market close. Analysts predict a loss of $0.27 per share and revenue of $25.96 million for the quarter. The company previously reported a loss of $0.16 per share and revenue of $35.75 million. Lifecore has a market cap of $145.05 million and a P/E ratio of -3.95. Institutional investors hold 83.36% of the stock, with ratings ranging from 'Buy' to 'Sell' from various analysts. The average rating is 'Hold' with a target price of $5.50.

Market Beat

Lifecore Biomedical (LFCR) to Release Earnings on Thursday